REGENXBIO Inc. (NASDAQ:RGNX) Shares Bought by GSA Capital Partners LLP

Key Points

• GSA Capital Partners LLP increased its stake in REGENXBIO Inc. by 659.7% during the first quarter, owning approximately 0.26% of the company and holding shares valued at about $939,000.
• REGENXBIO reported $0.12 earnings per share for the last quarter, missing the consensus estimate of $0.41, and had a revenue of $89.01 million, below expectations of $105.35 million.
• Brokerages have mixed opinions on REGENXBIO, with Goldman Sachs lowering their price target to $12.00 while Chardan Capital maintained a buy rating with a target of $52.00, resulting in a consensus rating of "Moderate Buy."

GSA Capital Partners LLP boosted its holdings in shares of REGENXBIO Inc. (NASDAQ:RGNX - Free Report) by 659.7% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 131,329 shares of the biotechnology company's stock after acquiring an additional 114,043 shares during the period. GSA Capital Partners LLP owned about 0.26% of REGENXBIO worth $939,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also added to or reduced their stakes in RGNX. FNY Investment Advisers LLC purchased a new stake in shares of REGENXBIO in the 1st quarter worth approximately $35,000. KLP Kapitalforvaltning AS bought a new position in REGENXBIO in the fourth quarter worth approximately $54,000. Dynamic Technology Lab Private Ltd purchased a new stake in REGENXBIO during the fourth quarter worth $79,000. Laurion Capital Management LP purchased a new stake in REGENXBIO during the fourth quarter worth $79,000. Finally, Pallas Capital Advisors LLC bought a new stake in REGENXBIO during the 1st quarter valued at $74,000. Hedge funds and other institutional investors own 88.08% of the company's stock.

Analyst Upgrades and Downgrades

RGNX has been the subject of several recent research reports. The Goldman Sachs Group reduced their price target on REGENXBIO from $14.00 to $12.00 and set a "neutral" rating for the company in a research report on Thursday, April 17th. Chardan Capital reiterated a "buy" rating and issued a $52.00 target price on shares of REGENXBIO in a research note on Monday, June 9th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, REGENXBIO presently has a consensus rating of "Moderate Buy" and a consensus target price of $31.63.

Insider Activity at REGENXBIO

In related news, Director Kenneth T. Mills sold 20,602 shares of REGENXBIO stock in a transaction that occurred on Monday, May 12th. The shares were sold at an average price of $7.91, for a total value of $162,961.82. Following the completion of the sale, the director directly owned 475,103 shares in the company, valued at $3,758,064.73. This trade represents a 4.16% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 12.79% of the stock is owned by insiders.

REGENXBIO Stock Down 3.8%

Shares of REGENXBIO stock traded down $0.32 during trading on Friday, reaching $8.19. The company's stock had a trading volume of 539,624 shares, compared to its average volume of 559,914. REGENXBIO Inc. has a 1-year low of $5.03 and a 1-year high of $13.48. The company has a 50-day simple moving average of $8.88 and a two-hundred day simple moving average of $8.01. The company has a market cap of $410.81 million, a price-to-earnings ratio of -2.63 and a beta of 1.11.

REGENXBIO (NASDAQ:RGNX - Get Free Report) last issued its quarterly earnings results on Monday, May 12th. The biotechnology company reported $0.12 earnings per share for the quarter, missing the consensus estimate of $0.41 by ($0.29). REGENXBIO had a negative return on equity of 53.29% and a negative net margin of 100.62%. The business had revenue of $89.01 million during the quarter, compared to analyst estimates of $105.35 million. As a group, analysts anticipate that REGENXBIO Inc. will post -4.84 earnings per share for the current year.

REGENXBIO Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.